Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302)

CONCLUSIONS: The primary endpoint was achieved. Nab-paclitaxel was well tolerated and showed anti-tumor activity in patients with previously treated NSCLC. This study demonstrates a low degree of concordance in CIPN grading between physicians and patients.TRIAL REGISTRATION: University hospital Medical Information Network Clinical Trial Registry (ID: UMIN000012343).PMID:35958345 | PMC:PMC9359941 | DOI:10.21037/tlcr-22-89

Source: Cell Research - August 12, 2022 Category: Cytology Authors: Satoshi Shoji Satoru Miura Satoshi Watanabe Aya Ohtsubo Koichiro Nozaki Yu Saida Kosuke Ichikawa Rie Kondo Tomohiro Tanaka Kenichi Koyama Hiroshi Tanaka Masaaki Okajima Tetsuya Abe Takeshi Ota Takashi Ishida Masato Makino Akira Iwashima Kazuhiro Sato Naoy Source Type: research